Myriad 决定,第 10 页。

IF 7.7 2区 生物学 Q1 GENETICS & HEREDITY
Jacob S Sherkow, Robert Cook-Deegan, Henry T Greely
{"title":"Myriad 决定,第 10 页。","authors":"Jacob S Sherkow, Robert Cook-Deegan, Henry T Greely","doi":"10.1146/annurev-genom-010323-011239","DOIUrl":null,"url":null,"abstract":"<p><p>A decade ago, the US Supreme Court decided <i>Association for Molecular Pathology v. Myriad Genetics, Inc.</i>, concluding that isolated genes were not patentable subject matter. Beyond being a mere patent dispute, the case was a political and cultural phenomenon, viewed as a harbinger for the health of the biotechnology industry. With a decade of perspective, though, <i>Myriad</i>'s impact seems much narrower. The law surrounding patentable subject matter-while greatly transformed-only centered on <i>Myriad</i> in small part. The case had only a modest impact on patenting practices both in and outside the United States. And persistent efforts to legislatively overturn the decision have not borne fruit. The significance of <i>Myriad</i> thus remains, even a decade later, hidden by larger developments in science and law that have occurred since the case was decided.</p>","PeriodicalId":8231,"journal":{"name":"Annual review of genomics and human genetics","volume":null,"pages":null},"PeriodicalIF":7.7000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The <i>Myriad</i> Decision at 10.\",\"authors\":\"Jacob S Sherkow, Robert Cook-Deegan, Henry T Greely\",\"doi\":\"10.1146/annurev-genom-010323-011239\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>A decade ago, the US Supreme Court decided <i>Association for Molecular Pathology v. Myriad Genetics, Inc.</i>, concluding that isolated genes were not patentable subject matter. Beyond being a mere patent dispute, the case was a political and cultural phenomenon, viewed as a harbinger for the health of the biotechnology industry. With a decade of perspective, though, <i>Myriad</i>'s impact seems much narrower. The law surrounding patentable subject matter-while greatly transformed-only centered on <i>Myriad</i> in small part. The case had only a modest impact on patenting practices both in and outside the United States. And persistent efforts to legislatively overturn the decision have not borne fruit. The significance of <i>Myriad</i> thus remains, even a decade later, hidden by larger developments in science and law that have occurred since the case was decided.</p>\",\"PeriodicalId\":8231,\"journal\":{\"name\":\"Annual review of genomics and human genetics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":7.7000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annual review of genomics and human genetics\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1146/annurev-genom-010323-011239\",\"RegionNum\":2,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/6 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"GENETICS & HEREDITY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annual review of genomics and human genetics","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1146/annurev-genom-010323-011239","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/6 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

摘要

十年前,美国最高法院对分子病理学协会诉 Myriad Genetics, Inc.除了单纯的专利纠纷之外,该案还成为一种政治和文化现象,被视为生物技术产业健康发展的先兆。不过,从十年前的角度来看,Myriad 案的影响似乎要小得多。围绕专利主题的法律虽然发生了巨大变化,但Myriad案只是其中的一小部分。该案对美国国内外的专利实践影响不大。而立法推翻该判决的不懈努力也没有取得成果。因此,即使在十年后的今天,Myriad案的意义仍被该案判决后科学和法律领域的更大发展所掩盖。预计《基因组学与人类遗传学年刊》第 25 卷的最终在线出版日期为 2024 年 8 月。修订后的预计日期请参见 http://www.annualreviews.org/page/journal/pubdates。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The Myriad Decision at 10.

A decade ago, the US Supreme Court decided Association for Molecular Pathology v. Myriad Genetics, Inc., concluding that isolated genes were not patentable subject matter. Beyond being a mere patent dispute, the case was a political and cultural phenomenon, viewed as a harbinger for the health of the biotechnology industry. With a decade of perspective, though, Myriad's impact seems much narrower. The law surrounding patentable subject matter-while greatly transformed-only centered on Myriad in small part. The case had only a modest impact on patenting practices both in and outside the United States. And persistent efforts to legislatively overturn the decision have not borne fruit. The significance of Myriad thus remains, even a decade later, hidden by larger developments in science and law that have occurred since the case was decided.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
14.90
自引率
1.10%
发文量
29
期刊介绍: Since its inception in 2000, the Annual Review of Genomics and Human Genetics has been dedicated to showcasing significant developments in genomics as they pertain to human genetics and the human genome. The journal emphasizes genomic technology, genome structure and function, genetic modification, human variation and population genetics, human evolution, and various aspects of human genetic diseases, including individualized medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信